Indazol-Pyrimidine Hybrids: Design, Synthesis, and Antiproliferative Activity Against Human Cancer Cell Lines.

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Pharmacology

Background:

• Cancer remains a leading cause of mortality worldwide, necessitating the development of novel therapeutic agents.
• Indazol-pyrimidine scaffolds have emerged as promising structures in anticancer drug discovery.

Purpose of the Study:

• To synthesize a new series of indazol-pyrimidine derivatives.
• To evaluate the in vitro cytotoxic activity of these derivatives against human cancer cell lines.
• To identify lead compounds with potent anti-proliferative potential.

Main Methods:

• Chemical synthesis of indazol-pyrimidine derivatives (compounds 4a-h and 5a-h).
• In vitro cytotoxicity evaluation using the MTT assay against MCF-7, A549, and Caco-2 cancer cell lines.
• Determination of half-maximal inhibitory concentration (IC50) values.
• Molecular docking and molecular dynamics studies to predict binding affinity and stability.

Main Results:

• Several synthesized compounds exhibited significant cytotoxic activity.
• Compound 5f demonstrated potent and broad-spectrum cytotoxicity against MCF-7, A549, and Caco-2 cells, with IC50 values in the low micromolar range.
• Compounds 4a, 4c, 4d, 5a, 4b, and 5h also showed notable cytotoxic or anti-proliferative effects against specific cell lines, outperforming the reference drug Staurosporine in some cases.
• Molecular docking indicated strong binding affinity of compound 5f to the c-Kit tyrosine kinase protein, further supported by molecular dynamics simulations.

Conclusions:

• The synthesized indazol-pyrimidine derivatives represent a promising class of anticancer agents.
• Compound 5f is identified as a potent lead candidate for further investigation due to its strong cytotoxic effects and favorable binding interactions.
• Further studies are warranted to explore the therapeutic potential and mechanism of action of these novel compounds.